

Wholesale Acquisition Cost (WAC) Disclosure for Connecticut Prescribing Practitioners and Pharmacists

This information is provided pursuant to Connecticut law, which requires pharmaceutical manufacturers to disclose the list price of a prescription drug when providing information about the drug to prescribing practitioners or pharmacists in Connecticut. Wholesale Acquisition Cost (WAC) represents the manufacturer’s published list price to wholesalers and does not reflect the actual cost paid by patients. The WAC of Lumvoa™ (veligrotug-vvze) as of June 26, 2026 is provided below.

Product/NDC ¹	WAC per vial ^{2*}	Total treatment cost (based on an 82-kg patient) ^{1-4†}
Lumvoa NDC: 85166-001-01	\$44,800	\$448,000

*The WAC is the manufacturer’s undiscounted list price for a pharmaceutical product when it is sold to wholesalers, distributors, or other direct purchasers. The WAC does not represent an actual transaction price and does not include discounts, rebates, or other reductions in price.
†Based on 10 mg/kg dosage every 3 weeks for 5 infusions, with vial counts rounded up to the nearest whole vial. Assumes a patient weight of 82 kg, which is consistent with the average patient weight observed in the THRIVE trial and aligns with the CDC-reported average adult weight.^{1,3,4}
CDC, Centers for Disease Control and Prevention; NDC, National Drug Code.
References: **1.** Lumvoa™ (veligrotug-vvze) prescribing information. Viridian Therapeutics, Inc. 2026. **2.** Data on file. Viridian Therapeutics, Inc. June 26, 2026. **3.** Anthropomorphic Reference Data for Children and Adults: United States, August 2021-2023. National Center for Health Statistics (US). June 25, 2025. Accessed June 1, 2026. <https://stacks.cdc.gov/view/cdc/174595> **4.** Data on file. Viridian Therapeutics, Inc. August 22, 2025.

